Lymphoma Therapeutics Market Expected to Reach $35,207.45 Million by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Lymphoma Therapeutics Market," The lymphoma therapeutics market size was valued at $15,691.45 million in 2022 and is estimated to reach $35,207.45 million by 2032, exhibiting a CAGR of 8.4% from 2023 to 2032. 

Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It targets lymphocytes in the lymph nodes, spleen, thymus, and bone marrow and impairs the immune response of the body. As a result, the patient develops swelling in the lymph nodes, high fever, weight loss, dyspnea, and fatigue.

Some of the commonly used lymphoma therapeutics include radiation, chemotherapy, monoclonal antibody therapy, active surveillance, bone marrow transplantation, and immunotherapy drugs. These therapeutics are widely used for the treatment of both Hodgkin and non-Hodgkin lymphomas.  

The key factors that drive the growth of the lymphoma therapeutics market share are rise in prevalence of non-Hodgkin lymphoma and increase in number of pipeline drugs. For instance, according to the report published by the American Society of Clinical Oncology (ASCO), an estimated 8,830 people (4,850 men and 3,980 women) in the U.S. will be diagnosed with Hodgkin lymphoma in 2023.

In addition, globally, an estimated 83,087 people were diagnosed with Hodgkin lymphoma in 2020. It is estimated that 900 deaths (540 men and 360 women) from this disease will occur in the U.S. in 2023. From 2011 to 2020, the death rate dropped by 4% every year. In 2020, an estimated 23,376 people globally died from Hodgkin lymphoma. Hodgkin lymphoma affects both children and adults.

Furthermore, rise in awareness of lymphoma cancer and surge in investments in R&D activities by pharmaceutical companies for the development of more target specific lymphoma therapeutics boost the growth of the lymphoma treatment market.  

However, the stringent regulatory compliance for the approval of lymphoma therapeutics and potential side effects of lymphoma therapeutics such as fatigue, nausea, and hair loss hamper the growth of the lymphoma treatment market. Conversely, rise in geriatric population and increase in awareness about lymphoma and its treatment options among the public in emerging economies such as India, China, Mexico, and Brazil are anticipated to create potential opportunities for market expansion.   

On the basis of disease type, the lymphoma therapeutics market analysis is segmented into Hodgkin lymphoma and non-Hodgkin lymphoma. In 2022, the non-Hodgkin lymphoma segment accounted for the largest share of the market and is projected to exhibit the fastest market growth during the forecast period, owing to rise in prevalence of non-Hodgkin lymphoma and surge in development of new and more effective drugs by key market players to treat non-Hodgkin lymphoma (NHL).   

However, the Hodgkin lymphoma segment is expected to witness considerable market growth during the forecast period. Owing to rise in the prevalence of Hodgkin's lymphoma and increase in the availability of a large number of lymphoma therapeutics to treat Hodgkin lymphoma.      

By treatment type, the lymphoma treatment market size is categorized into immune therapy, chemotherapy, targeted therapy, and radiation therapy. The immune therapy segment was the major shareholder in 2022 and is anticipated to continue the same trend in the coming future, owing to advancement in immunology, increase in availability of immune therapies, and rise in number of product approvals across the world.   

However, the targeted therapy segment is expected to witness fastest CAGR during the forecast period. Owing to rise in prevalence of Hodgkin and non-Hodgkin lymphoma and advantages offered by targeted therapies such as the accuracy of the therapy in the targeting of the cancer cells.       

As per route of administration, the lymphoma therapeutics market is bifurcated into oral route and injectables. In 2022, the injectables segment garnered maximum share of the market and is projected to dominate during the forecast period, owing to rise in investment in R&D activities by pharmaceutical companies for the development of technologically advanced injectable dosage forms for lymphoma.   

However, oral route segment is expected to witness considerable market growth during the forecast period. Owing to rise in prevalence of cancer and chronic diseases such as non-Hodgkin and Hodgkin lymphoma worldwide and increase in number of key players providing a wide range of oral lymphoma therapeutics.       

Depending on distribution channel, the lymphoma therapeutics market is segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment exhibited the highest growth in 2022, and is anticipated to lead during the forecast period, owing to the fact that lymphoma therapeutics are mostly dispensed in hospital pharmacies for hospitalized patients. In addition, rise in consumption of lymphoma therapeutics in hospitals acts as the key driver of the segment.   

However, retail pharmacies segment is expected to witness considerable market growth during the forecast period. Owing to increase in prevalence of non-Hodgkin and Hodgkin lymphoma and easy availability of lymphoma therapeutics in retail pharmacy.     

North America accounted for the majority share in 2022 and is anticipated to remain dominant during the forecast period, owing to rise in the prevalence of lymphoma, developments in lymphoma therapeutics, including targeted therapies and immunotherapies and surge in number of new product launches by key market players in this region. For instance, in January 2023 U.S. FDA approved Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, for adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor.  

Asia-Pacific is expected to witness growth at the highest rate during the lymphoma therapeutics market forecast due to rise in prevalence of lymphoma and increase in initiatives in R&D activities for the development of advanced therapies for the treatment of lymphomas. Furthermore, rise in awareness of available treatment options for lymphoma and surge in geriatric population in the developing countries such as India, China, Japan, and South Korea contribute to the growth of the market.

The key players that operate in the lymphoma therapeutics industry are AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lily and Company, F. Hoffman La-Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen Inc., Teva Pharmaceutical Industries Ltd., and Pfizer Inc.     

KEY FINDINGS OF THE STUDY  

• By disease type, the non-Hodgkin lymphoma segment was the highest contributor to the market in 2022.  

• By treatment type, the immune therapy segment was the highest contributor to the lymphoma treatment industry in 2022.  

• By route of administration, the injectable segment was the highest contributor to the market in 2022.  

• By distribution channel, the hospital pharmacies dominated the market in 2022 and are expected to remain dominant during the forecast period.  

• By region, North America garnered the largest lymphoma therapeutics market trends in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.